GIV’AT SHMUEL, Israel & ATLANTA--(BUSINESS WIRE)--June 21, 2006--GammaCan International (OTCBB:GCAN - News), and Life Therapeutics (ASX:LFE - News) today announced a joint effort to develop VitiGam, an innovative anti-cancer product designed to target metastatic malignant melanoma patients with Stage III and IV disease, in connection with a grant to be provided by the BIRD Foundation.
